Synergistic cytotoxicity of the ribonucleotide reductase inhibitor didox (3,4-dihydroxy-benzohydroxamic acid) and the alkylating agent carmustine (BCNU) in 9L rat gliosarcoma cells and DAOY human medulloblastoma cells

Cancer Chemotherapy and Pharmacology

Volumn 54, Issue 2, 2004, Pages 139-145

  Horvath, Zsuzsanna ^a   Höchtl, Thomas ^a   Bauer, Wolfgang ^a   Fritzer Szekeres, Monika ^a   Elford, Howard L ^b   Szekeres, Thomas ^a   Tihan, Tarik ^c  

^a UNIVERSITY OF VIENNA   (Austria)

^b Molecules for Health Inc   (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

BCNU; Didox; Glioblastoma; Ribonucleotide reductase; Synergistic combination chemotherapy

Indexed keywords

ALKYLATING AGENT; CARMUSTINE; COMPLEMENTARY DNA; DEOXYCYTIDINE TRIPHOSPHATE; DEOXYGUANOSINE TRIPHOSPHATE; DNA POLYMERASE; ENZYME INHIBITOR;

ANIMAL CELL; ARTICLE; CHEMICAL ANALYSIS; CYTOTOXICITY; DNA MICROARRAY; DNA REPAIR; DNA SYNTHESIS; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INCUBATION TIME; NONHUMAN; PRIORITY JOURNAL; RAT; SARCOMA CELL; UPREGULATION;

EID: 3843093902     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-004-0795-0     Document Type: Article

References (22)

1. Ali-Osman F, Srivenugopal K, Berger MS, Stein DE (1990) DNA interstrand cross-linking and strand break repair in human glioma cell lines of varying [1,3-bis(2-chloroethyl)-nitro-sourea] resistance. Anticancer Res 10:677-682
2. Carmichael J, Cantwell BM, Mannix KA, Veale D, Elford HL, Blackie R, Kerr DJ, Kaye SB, Harris AL (1990) A phase I and pharmacokinetic study of didox administered by 36 h infusion. The Cancer Research Campaign Phase I/II Clinical Trials Committee. Br J Cancer 61:447-450
3. Chou TC, Talalay P (1984) Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors. Adv Enzyme Regul 22:27-55
4. Colvin M, Brundett RB, Cowens W, Jardine I, Ludlum DB (1976) A chemical basis for the antitumor activity of chloroethylnitrosoureas. Biochem Pharmacol 25:695-699
5. Elford HL, Freese M, Passamani E, Morris HP (1970) Ribonucleotide reductase and cell proliferation. I. Variations of ribonucleotide reductase activity with tumor growth rate in a series of rat hepatomas. J Biol Chem 245:5228-5233
6. Esteller M, Garcia-Foncillas J, Andion E, Goodman SN, Hidalgo OF, Vanaclocha V, Baylin SB, Herman JG (2000) Inactivation of the DNA-repair gene MGMT and the clinical response of gliomas to alkylating agents. N Engl J Med 343:1350-1354
7. Figul M, Soling A, Dong HJ, Chou TC, Rainov NG (2003) Combined effects of temozolomide and the ribonucleotide reductase inhibitors didox and trimidox in malignant brain tumor cells. Cancer Chemother Pharmacol 52:41-46
8. Frazier JL, Wang PP, Case D, Tyler BM, Pradilla G, Weingart JD, Brem H (2003) Local delivery of minocycline and systemic BCNU have synergistic activity in the treatment of intracranial glioma. J Neurooncol 64:203-209
9. Garrett C, Santi DV (1979) A rapid and sensitive high pressure liquid chromatography assay for deoxyribonucleotide triphosphates in cell extracts. Anal Biochem 99:268-273
10. Kyritsis AP (1993) Chemotherapy for malignant gliomas. Oncology (Huntingt) 7:93-100; discussion 103, 106
11. Levin VA, Wilson CB, Davis R, Wara W, Pischer TL, Irwin L (1979) Preliminary results of a phase III comparison study of BCNU, hydroxyurea and radiation to BCNU and radiation. Int J Radiat Oncol Biol Phys 5:1573-1576
12. Levin VA, Wilson CB, Davis R, Wara WM, Pischer TL, Irwin L (1979) A phase III comparison of BCNU, hydroxyurea, and radiation therapy to BCNU and radiation therapy for treatment of primary malignant gliomas. J Neurosurg 51:526-532
13. Levin VA, Wara WM, Davis RL, Vestnys P, Resser KJ, Yatsko K, Nutik S, Gutin PH, Wilson CB (1985) Phase III comparison of BCNU and the combination of procarbazine, CCNU, and vincristine administered after radiotherapy with hydroxyurea for malignant gliomas. J Neurosurg 63:218-223
14. Olivi A, Grossman SA, Tatter S, Barker F, Judy K, Olsen J, Bruce J, Hilt D, Fisher J, Piantadosi S (2003) Dose escalation of carmustine in surgically implanted polymers in patients with recurrent malignant glioma: a New Approaches to Brain Tumor Therapy CNS Consortium trial. J Clin Oncol 21:1845-1849
15. Piepmeier JM, Rabidou N, Schold SC Jr, Bitonti AJ, Prakash NJ, Bush TL (1996) In vitro and in vivo inhibition of glioblastoma and neuroblastoma with MDL101731, a novel ribonucleoside diphosphate reductase inhibitor. Cancer Res 56:359-361
16. Rosenberger G, Fuhrmann G, Grusch M, Fassl S, Elford HL, Smid K, Peters GJ, Szekeres T, Krupitza G (2000) The ribonucleotide reductase inhibitor trimidox induces c-myc and apoptosis of human ovarian carcinoma cells. Life Sci 67:3131-3142
17. Rubens RD, Kaye SB, Soukop M, Williams CJ, Brampton MH, Harris AL (1991) Phase II trial of didox in advanced breast cancer. Cancer Research Campaign Phase I/II Clinical Trials Committee. Br J Cancer 64:1187-1188
18. Sipos EP, Tyler B, Piantadosi S, Burger PC, Brem H (1997) Optimizing interstitial delivery of BCNU from controlled release polymers for the treatment of brain tumors. Cancer Chemother Pharmacol 39:383-389
19. Szekeres T, Fritzer-Szekeres M, Elford HL (1997) The enzyme ribonucleotide reductase: target for antitumor and anti-HIV therapy. Crit Rev Clin Lab Sci 34:503-528
20. Takeda E, Weber G (1981) Role of ribonucleotide reductase in expression in the neoplastic program. Life Sci 28:1007-1014
21. Tihan T, Elford HL, Cory JG (1991) Studies on the mechanism of inhibition of L-1210 cell growth by 3,4-dihydroxybenzamic acid and 3,4- dihydrohybenzamidoxime. Adv Enzyme Regul 31:71-83
22. Van't Riet B, Wampler GL, Elford HL (1979) Synthesis of hydroxy- and amino-substituted benzohydroxamic acids: inhibition of ribonucleotide reductase and antitumor activity. J Med Chem 22:589-592